FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2160367631> ?p ?o ?g. }

• W2160367631 abstract "Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer that is diagnosed in approximately 15% of all human breast cancer (BrCa) patients. Currently, no targeted therapies exist for this subtype of BrCa and prognosis remains poor. Our laboratory has previously identified a proliferation/DNA repair/cell cycle gene signature (Tag signature) that is characteristic of human TNBC. We hypothesize that targeting the dysregulated biological networks in the Tag gene signature will lead to the identification of improved combination therapies for TNBC. Cross-species genomic analysis was used to identify human breast cancer cell lines that express the Tag signature. Knock-down of the up-regulated genes in the Tag signature by siRNA identified several genes that are critical for TNBC cell growth. Small molecule inhibitors to two of these genes were analyzed, alone and in combination, for their effects on cell proliferation, cell cycle, and apoptosis in vitro and tumor growth in vivo. Synergy between the two drugs was analyzed by the Chou-Talalay method. A custom siRNA screen was used to identify targets within the Tag signature that are critical for growth of TNBC cells. Ribonucleotide reductase 1 and 2 (RRM1 and 2) and checkpoint kinase 1 (CHK1) were found to be critical targets for TNBC cell survival. Combination therapy, to simultaneously attenuate cell cycle checkpoint control through inhibition of CHK1 while inducing DNA damage with gemcitabine, improved therapeutic efficacy in vitro and in xenograft models of TNBC. This combination therapy may have translational value for patients with TNBC and improve therapeutic response for this aggressive form of breast cancer." @default.
• W2160367631 created "2016-06-24" @default.
• W2160367631 creator A5001531078 @default.
• W2160367631 creator A5001893199 @default.
• W2160367631 creator A5015255621 @default.
• W2160367631 creator A5022123787 @default.
• W2160367631 creator A5027370466 @default.
• W2160367631 creator A5029952151 @default.
• W2160367631 creator A5036886762 @default.
• W2160367631 creator A5052362487 @default.
• W2160367631 creator A5065356566 @default.
• W2160367631 creator A5073696429 @default.
• W2160367631 creator A5078151501 @default.
• W2160367631 creator A5080778766 @default.
• W2160367631 date "2012-07-19" @default.
• W2160367631 modified "2023-10-08" @default.
• W2160367631 title "Cross-species genomic and functional analyses identify a combination therapy using a CHK1 inhibitor and a ribonucleotide reductase inhibitor to treat triple-negative breast cancer" @default.
• W2160367631 cites W1966343286 @default.
• W2160367631 cites W1969473373 @default.
• W2160367631 cites W1972416794 @default.
• W2160367631 cites W2003029412 @default.
• W2160367631 cites W2004329237 @default.
• W2160367631 cites W2018556537 @default.
• W2160367631 cites W2020714490 @default.
• W2160367631 cites W2025228190 @default.
• W2160367631 cites W2039894516 @default.
• W2160367631 cites W2045937534 @default.
• W2160367631 cites W2082318061 @default.
• W2160367631 cites W2083173501 @default.
• W2160367631 cites W2087858299 @default.
• W2160367631 cites W2092890170 @default.
• W2160367631 cites W2101172600 @default.
• W2160367631 cites W2103041841 @default.
• W2160367631 cites W2105768236 @default.
• W2160367631 cites W2109554640 @default.
• W2160367631 cites W2116760308 @default.
• W2160367631 cites W2118605519 @default.
• W2160367631 cites W2134493631 @default.
• W2160367631 cites W2135548733 @default.
• W2160367631 cites W2140990686 @default.
• W2160367631 cites W2141055911 @default.
• W2160367631 cites W2141223216 @default.
• W2160367631 cites W2142739240 @default.
• W2160367631 cites W2144465725 @default.
• W2160367631 cites W2159171427 @default.
• W2160367631 cites W2161426850 @default.
• W2160367631 cites W4240695995 @default.
• W2160367631 doi "https://doi.org/10.1186/bcr3230" @default.
• W2160367631 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3680937" @default.
• W2160367631 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22812567" @default.
• W2160367631 hasPublicationYear "2012" @default.
• W2160367631 type Work @default.
• W2160367631 sameAs 2160367631 @default.
• W2160367631 citedByCount "25" @default.
• W2160367631 countsByYear W21603676312013 @default.
• W2160367631 countsByYear W21603676312014 @default.
• W2160367631 countsByYear W21603676312015 @default.
• W2160367631 countsByYear W21603676312016 @default.
• W2160367631 countsByYear W21603676312017 @default.
• W2160367631 countsByYear W21603676312018 @default.
• W2160367631 countsByYear W21603676312019 @default.
• W2160367631 countsByYear W21603676312020 @default.
• W2160367631 countsByYear W21603676312021 @default.
• W2160367631 countsByYear W21603676312022 @default.
• W2160367631 crossrefType "journal-article" @default.
• W2160367631 hasAuthorship W2160367631A5001531078 @default.
• W2160367631 hasAuthorship W2160367631A5001893199 @default.
• W2160367631 hasAuthorship W2160367631A5015255621 @default.
• W2160367631 hasAuthorship W2160367631A5022123787 @default.
• W2160367631 hasAuthorship W2160367631A5027370466 @default.
• W2160367631 hasAuthorship W2160367631A5029952151 @default.
• W2160367631 hasAuthorship W2160367631A5036886762 @default.
• W2160367631 hasAuthorship W2160367631A5052362487 @default.
• W2160367631 hasAuthorship W2160367631A5065356566 @default.
• W2160367631 hasAuthorship W2160367631A5073696429 @default.
• W2160367631 hasAuthorship W2160367631A5078151501 @default.
• W2160367631 hasAuthorship W2160367631A5080778766 @default.
• W2160367631 hasBestOaLocation W21603676311 @default.
• W2160367631 hasConcept C104292427 @default.
• W2160367631 hasConcept C104317684 @default.
• W2160367631 hasConcept C105696609 @default.
• W2160367631 hasConcept C121608353 @default.
• W2160367631 hasConcept C150194340 @default.
• W2160367631 hasConcept C2779733811 @default.
• W2160367631 hasConcept C2780110267 @default.
• W2160367631 hasConcept C2781230642 @default.
• W2160367631 hasConcept C29537977 @default.
• W2160367631 hasConcept C4710235 @default.
• W2160367631 hasConcept C50001416 @default.
• W2160367631 hasConcept C502942594 @default.
• W2160367631 hasConcept C530470458 @default.
• W2160367631 hasConcept C54355233 @default.
• W2160367631 hasConcept C62112901 @default.
• W2160367631 hasConcept C71924100 @default.
• W2160367631 hasConcept C86803240 @default.
• W2160367631 hasConcept C96232424 @default.
• W2160367631 hasConceptScore W2160367631C104292427 @default.
• W2160367631 hasConceptScore W2160367631C104317684 @default.
• W2160367631 hasConceptScore W2160367631C105696609 @default.
• W2160367631 hasConceptScore W2160367631C121608353 @default.

• next